ApoCell, Inc. Sustainability Profile
ApoCell, Inc., a leading player in the biotechnology sector, is headquartered in the United States, with significant operations across various regions. Founded in 2004, the company has established itself as a pioneer in the development of advanced diagnostic solutions, particularly in the realm of personalised medicine and oncology. ApoCell's core offerings include innovative biomarker analysis and laboratory services that enable precise patient stratification and treatment optimisation. Their unique approach combines cutting-edge technology with a commitment to quality, setting them apart in a competitive market. With a strong focus on enhancing patient outcomes, ApoCell has achieved notable milestones, including collaborations with major pharmaceutical companies and contributions to clinical trials. Their dedication to advancing healthcare through science positions them as a trusted partner in the evolving landscape of personalised medicine.
DitchCarbon Score
How does ApoCell, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ApoCell, Inc.'s score of 20 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ApoCell, Inc.'s reported carbon emissions
ApoCell, Inc., headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported emissions figures. The company is a current subsidiary of Precision Medicine Group, LLC, which may influence its climate commitments and reporting practices. While ApoCell, Inc. does not have documented reduction targets or specific climate pledges, it is important to note that any potential climate initiatives or targets may be inherited from its parent organisation, Precision Medicine Group, LLC. This cascading relationship suggests that ApoCell may align with broader sustainability goals set by its parent company, although specific details are not provided. As the company continues to develop its environmental strategy, it may consider adopting industry-standard climate initiatives, such as Science-Based Targets (SBTi) or participation in the Carbon Disclosure Project (CDP), which are common practices among organisations aiming to reduce their carbon footprint. However, without explicit commitments or data, the current status of ApoCell's climate initiatives remains unclear.
How Carbon Intensive is ApoCell, Inc.'s Industry?
How Carbon Intensive is ApoCell, Inc.'s Location?
ApoCell, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
ApoCell, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
